Scientific research, clinical trials and evidence base
9 articles
Detailed analysis of the largest tirzepatide study: methodology, dosing, primary and secondary outcomes, safety profile and comparison with other SURMOUNT programs.
17,604 patients, 4 years of follow-up, 20% reduction in heart attack and stroke risk. Breaking down the SELECT study that became the basis for FDA's new cardiovascular indication.
Epitalon is a tetrapeptide Ala-Glu-Asp-Gly from Khavinson's school that activates telomerase. Anisimov 2006: +25-50% mice lifespan extension. 10-day protocol, limitations, synergy.
NMN increases NAD+ by 29% in 8 weeks. Harvard research, 500-1000 mg protocol, comparison with NR and injections. What actually works for anti-aging.
Cagrilintide (Amylin) is a long-acting analog of the amylin hormone. It works through a different pathway than Ozempic or Mounjaro. CagriSema showed -22.7% weight loss over 68 weeks.
What to expect on Retatrutide, side effect profile, and how the triple mechanism changes the experience compared to Mounjaro and Ozempic.
Ready to lose weight with Mounjaro?
Free specialist consultation — we'll select the right dose and program for you
The first drug to activate three receptors simultaneously: GLP-1, GIP, and glucagon. Minus 24% weight in 48 weeks — but should you start with this one?
GLP-1 pipeline full of innovations: orforglipron, survodutide, amycretin, CagriSema. Understanding when they'll arrive and why you shouldn't wait for the 'perfect' drug.
Anastasiia Shapoval
What do people really lose on Mounjaro and Ozempic? Analysis of clinical data, verified DOZA client cases, and current Retatrutide research. No promises — just numbers.
Anastasiia Shapoval